All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Mounjaro Results After 1 Year: What to Expect

What do Mounjaro results after 1 year look like for weight loss and blood sugar? Clinical data, month-by-month timeline, and practical tips for success.

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

Mounjaro Results After 1 Year: What to Expect custom 2026 header image for GLP-1 Weight Loss
Custom header image for Mounjaro Results After 1 Year: What to Expect, GLP-1 Weight Loss, and better treatment decision-making.
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Search and AI answer brief

Practical answer: Mounjaro Results After 1 Year: What to Expect

What do Mounjaro results after 1 year look like for weight loss and blood sugar? Clinical data, month-by-month timeline, and practical tips for success.

Short answer

What do Mounjaro results after 1 year look like for weight loss and blood sugar? Clinical data, month-by-month timeline, and practical tips for success.

Search intent

This page answers a specific GLP-1 Weight Loss question rather than a generic overview.

What to verify

semaglutide, tirzepatide, retatrutide, peptide evidence quality

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

See your GLP-1 options in about 2 minutes. Free and private. See my options →

What do Mounjaro results after 1 year look like for weight loss and blood sugar? Clinical data, month-by-month timeline, and practical tips for success.

Mounjaro (tirzepatide) has quickly become one of the most talked-about medications for both type 2 diabetes and weight management. If you're wondering what Mounjaro results after 1 year look like, we have the clinical data and practical insights to help you plan ahead. As a dual GIP/GLP-1 receptor agonist, Mounjaro works through a unique mechanism that has produced standout results in clinical trials.

Average Weight Loss and A1C Improvements at 12 Months

The SURPASS clinical trial program studied Mounjaro in patients with type 2 diabetes, while the SURMOUNT trials focused on obesity without diabetes. Here is what the data shows at approximately one year:

  • For type 2 diabetes (SURPASS trials): Patients on Mounjaro 15 mg lost an average of 12.4 kg (27.3 lbs) over 40 to 52 weeks. A1C reductions averaged 2.0% to 2.3%, bringing many patients below the 7.0% target .
  • For obesity without diabetes (SURMOUNT-1[1]): Patients on 15 mg lost an average of 22.5% of body weight[1] (roughly 52 lbs from a starting weight of 231 lbs) over 72 weeks .

These numbers make Mounjaro one of the most effective prescription weight loss options currently available.

Month-by-Month Timeline on Mounjaro

  • Month 1 (2.5 mg): Titration phase. Weight loss is modest, typically 2 to 5 pounds. Many patients notice reduced hunger and some GI adjustment (nausea, bloating). Blood sugar improvements may begin within the first few weeks for diabetic patients.
  • Month 2 (5.0 mg): Appetite suppression strengthens. Cumulative weight loss of 5 to 10 pounds. Patients with diabetes often see their fasting glucose numbers drop noticeably.
  • Months 3 to 4 (7.5 mg): This is when many patients describe a "turning point." Cumulative loss of 12 to 20 pounds. Food cravings drop, portion sizes shrink naturally, and energy levels often improve.
  • Months 5 to 7 (10 mg to 15 mg): Rapid and visible progress. Cumulative loss of 20 to 35 pounds. Waist measurements decrease. Lab work typically shows meaningful improvements in A1C, triglycerides, and blood pressure.
  • Months 8 to 10: Weight loss continues but the rate begins to moderate. Cumulative loss of 28 to 45 pounds. The body is adjusting to a lower weight.
  • Months 11 to 12: Many patients approach their plateau on their current dose. Total loss of 25 to 55 pounds depending on dose, starting weight, and lifestyle adherence.

Side Effects Over the First Year

Knowing what to expect helps you stay on track:

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →
GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Illustration for Mounjaro Results After 1 Year: What to Expect
  • GI symptoms (months 1 to 3): Nausea affects about 12% to 18% of patients at each dose level. Diarrhea and constipation are also common early on. These symptoms typically peak during dose increases and then subside within 1 to 2 weeks.
  • Reduced appetite (ongoing): Most patients experience a sustained decrease in hunger. This is the primary therapeutic mechanism, not just a side effect.
  • Injection site reactions: Occasional redness or swelling at the injection site. Usually mild and short-lived.
  • Fatigue (months 1 to 4): Some patients report tiredness during caloric restriction. Adequate protein and hydration help.
  • Gallbladder issues: Rapid weight loss increases the risk of gallstones. Report any right-sided abdominal pain to your doctor .

How Mounjaro Compares to Other GLP-1 Options at 1 Year

For context, here is how Mounjaro's 1-year outcomes stack up:

  • Mounjaro 15 mg: 20% to 22% average body weight loss
  • Wegovy (semaglutide 2.4 mg): 15% to 17% average body weight loss
  • Ozempic (semaglutide 1.0 mg): 6% to 10% average body weight loss
  • Liraglutide (Saxenda): 5% to 8% average body weight loss[3]

Mounjaro's dual receptor mechanism appears to provide a meaningful advantage, particularly for patients who need to lose a larger percentage of their body weight . For a complete cost breakdown, see our best tirzepatide compounding pharmacies.

Practical Tips for Your First Year

  • Don't skip the titration: Mounjaro has five dose levels for a reason. Jumping ahead increases side effects without improving results.
  • Load up on protein: Target 1.0 to 1.2 grams of protein per kilogram of body weight daily. Protein shakes can help if appetite is very low.
  • Strength train 2 to 3 times weekly: Resistance exercise is the best defense against lean muscle loss during significant weight reduction.
  • Keep a food journal: Tracking what you eat helps you make intentional choices when appetite is suppressed.
  • Get labs done every 3 months: Monitor A1C, lipids, liver function, and kidney markers. Celebrate the improvements you see.
  • Stay hydrated: Drink at least 64 ounces of water daily. Dehydration worsens constipation and fatigue.

Frequently Asked Questions

Is Mounjaro the same as Zepbound?

Both contain tirzepatide as the active ingredient. Mounjaro is approved for type 2 diabetes, while Zepbound is approved specifically for chronic weight management. The dosing and medication are identical, but the FDA indications and insurance coverage differ.

What if I reach my goal weight before 12 months?

Your provider may reduce your dose to a maintenance level rather than continuing at the highest dose. The goal is to find the lowest effective dose that maintains your results while minimizing side effects.

Can I drink alcohol while taking Mounjaro?

Moderate alcohol consumption is generally acceptable, but Mounjaro can intensify the effects of alcohol since it slows gastric emptying. Start with small amounts and see how you respond. Avoid high-calorie cocktails that work against your weight loss goals .

Will my insurance cover Mounjaro for weight loss?

Coverage depends on your plan and diagnosis. Mounjaro is more commonly covered for type 2 diabetes than for weight management alone. If weight loss is your primary goal, ask your provider about Zepbound or compounded options $1,000-$1,200/mo (brand).

How long should I plan to stay on Mounjaro?

Current evidence supports long-term use. The SURMOUNT-4 trial[2] showed that patients who discontinued tirzepatide regained a significant portion of their lost weight within 12 months . Most providers recommend planning for ongoing treatment or a structured step-down approach.

Medical References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
  2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
  3. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]

Start Your Mounjaro Treatment with Expert Support

A year on Mounjaro can reshape your health in ways that go well beyond the number on the scale. To get the most from treatment, work with a provider who understands tirzepatide dosing, monitoring, and long-term planning. FormBlends connects you with licensed clinicians who specialize in GLP-1 and peptide therapy.

Book your clinical consultation today.

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
Mounjaro evidence source
Official source
Ozempic evidence source
Official source
Retatrutide evidence source
Official source
Saxenda evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Mounjaro Results After 1 Year: What to Expect, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Randomized trialTirzepatide evidence2025

Tirzepatide for Obesity Treatment and Diabetes Prevention

Supports newer discussion of obesity treatment and diabetes-prevention outcomes.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

Provider decision path

Use local research to choose a safer review path

Direct answer

Mounjaro Results After 1 Year: What to Expect is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

FormBlends Editorial Context

Reviewed May 14, 2026

What do Mounjaro results after 1 year look like for weight loss and blood sugar? Clinical data, month-by-month timeline, and practical tips for success. "Mounjaro Results After 1 Year: What to Expect" is meant to make a complicated topic easier to discuss, not to flatten it into a one-size answer. FormBlends frames it around patient education and clinical context, with extra attention to tirzepatide, provider access. Because this article has 7 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. If the next step affects treatment or sourcing, use the article to prepare questions for a licensed clinician.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Mounjaro Results After 1 Year

Mounjaro Results After 1 Year now carries extra 2026 context around semaglutide, tirzepatide, retatrutide, cash-pay pricing, safety signals, mounjaro, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation.

Instead of adding filler, this page keeps the named treatment terms, practical verification points, and next-step questions close to mounjaro results after 1 year what to expect.

Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting.

Mounjaro Results After 1 Year custom 2026 image for glp-1 weight loss on FormBlends

Custom 2026 image for Mounjaro Results After 1 Year, glp-1 weight loss, and better treatment decision-making.

Image description: Unique image for this page covering Mounjaro Results After 1 Year, glp-1 weight loss, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.